Concurrent Session I - INTESTINAL FAILURE: THROUGH THE LENS OF THE LONG TERM SURVIVORS
Moderators: Debora Duro, MD, MS, Salah Foundation Children's Hospital and Valeria Cohran, MD, Ann & Robert H Lurie Children's Hospital

Potential role of new fat emulsions
John Kerner, MD, Stanford University
Objectives:
  • Discuss the role of phytosterols in the etiology of intestinal failure associated liver disease
  • Review the differences between fat emulsions available in the U.S.
  • Describe specific indications for the two new fat emulsions
John Kerner
(Adobe PDF File)
Getting in line: Towards a clinical practice guideline for central venous catheter salvage in home parenteral nutrition patients
Bram Raphael, MD, Boston Children's Hospital
Objectives:
  • Preserving venous access can be critical to patient long-term survival
  • Factors impacting rates of success in central venous catheter salvage
  • Developing a central venous catheter salvage management algorithm, including antimicrobial locks
  • Future quality improvement opportunities
Bram Raphael
(Adobe PDF File)
218  MICROBIAL METABOLITES AS MARKERS OF INTESTINAL DYSBIOSIS IN PEDIATRIC SHORT  BOWEL SYNDROME. Arthur Kastl1, Lindsey Albenberg1, Christina Bales1, Michael Bennett1, Elliot Friedman2, William Mitchell1, Ceylan Tanes1, Natalie Terry1, Gary Wu2. 1Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA; 2Medicine, University of Pennsylvania, Philadelphia, PA, USA. 
Arthur Kastl
(Adobe PDF File)
Trophic growth factors: A practical view
Beth Carter, MD, Children's Hospital of Los Angeles
Objectives:
  • Review the timeline and design/outcomes of the trials for a new intestinotrophic agent recently FDA-approved for pediatric patients with SBS who are dependent on TPN
  • Summarize the medical monitoring guidelines for pediatric patients prescribed a new intestinotrophic agent for pediatric SBS patients who are TPN-dependent
  • Discuss the benefits of a multidisciplinary Intestinal Rehabilitation Center in providing multidisciplinary care for SBS and the importance of working together as a medical community to improve access and safe prescribing of a new intestinotrophic agent for ALL potential candidate patients
Beth Carter
(Adobe PDF File)